COMMON STI571: A COST-EFFECTIVE OPTION?

The arrival of common imatinib represents a notable chance for patients battling a certain type of cancer and other illnesses. Original brand-name imatinib, commonly known as Gleevec, carries a high price tag, frequently presenting a challenge for accessibility for some individuals. Common versio